ACRX logo

AcelRx Pharmaceuticals (ACRX) Net Income

Annual Net Income

-$18.40 M
-$66.15 M-138.52%

31 December 2023

3-Year Change

+47.59%
ACRX annual net profit is up +47.59% over the past 3 years

All-time High

$47.76 M
ACRX annual net profit is currently -138.52% below its historical high of $47.76 million

Annual Net Income Formula

Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
Annual Revenue$651.00 K
ACRX annual revenue is $651.00 thousand

ACRX Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly Net Income

-$4.52 M
-$3.16 M-232.87%

31 December 2023

3-Year Change

+42.95%
ACRX quarterly net profit is up +42.95% over the past 3 years

All-time High

$70.66 M
ACRX quarterly net profit is currently -106.39% below its historical high of $70.66 million
Quarterly Revenue$281.00 K
ACRX quarterly revenue is $281.00 thousand

ACRX Quarterly Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM Net Income

-$18.40 M
+$2.97 M+13.89%

31 December 2023

3-Year Change

+47.59%
ACRX TTM net profit is up +47.59% over the past 3 years

All-time High

$48.28 M
ACRX TTM net profit is currently -138.11% below its historical high of $48.28 million
TTM Revenue$651.00 K
ACRX TTM revenue is $651.00 thousand

ACRX TTM Net Income Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

ACRX Net Income Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years+47.6%+43.0%+47.6%
5 y5 years+65.5%+68.7%+65.5%

ACRX Net Income High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years
5 y5 years
alltimeall time-138.5%-106.4%-138.1%

AcelRx Pharmaceuticals Net Income History

DateAnnualQuarterlyTTM
Dec 2023
-$18.40 M(-138.5%)
-$4.52 M(+232.9%)
-$18.40 M(-13.9%)
Sept 2023
-
-$1.36 M(-69.0%)
-$21.36 M(-20.2%)
June 2023
-
-$4.37 M(-46.4%)
-$26.76 M(-155.4%)
Mar 2023
-
-$8.15 M(+8.9%)
$48.28 M(+1.1%)
Dec 2022
$47.76 M(-236.1%)
-$7.48 M(+10.9%)
$47.76 M(+0.9%)
Sept 2022
-
-$6.75 M(-109.6%)
$47.32 M(+3.6%)
June 2022
-
$70.66 M(-914.7%)
$45.70 M(-231.2%)
Mar 2022
-
-$8.67 M(+9.6%)
-$34.82 M(-0.8%)
Dec 2021
-$35.10 M(-13.1%)
-$7.92 M(-5.5%)
-$35.10 M(-2.8%)
Sept 2021
-
-$8.38 M(-15.0%)
-$36.10 M(-1.5%)
June 2021
-
-$9.85 M(+10.0%)
-$36.66 M(+9.7%)
Mar 2021
-
-$8.96 M(+0.4%)
-$33.41 M(-17.3%)
Dec 2020
-$40.38 M(-24.2%)
-$8.92 M(-0.1%)
-$40.38 M(-12.0%)
Sept 2020
-
-$8.93 M(+35.2%)
-$45.88 M(-7.7%)
June 2020
-
-$6.61 M(-58.5%)
-$49.69 M(-10.5%)
Mar 2020
-
-$15.93 M(+10.4%)
-$55.49 M(+4.2%)
Dec 2019
-$53.24 M(+12.9%)
-$14.42 M(+13.3%)
-$53.24 M(+3.6%)
Sept 2019
-
-$12.73 M(+2.6%)
-$51.38 M(+0.5%)
June 2019
-
-$12.41 M(-9.2%)
-$51.10 M(+3.8%)
Mar 2019
-
-$13.67 M(+8.9%)
-$49.23 M(+4.4%)
Dec 2018
-$47.15 M(-8.5%)
-$12.56 M(+0.8%)
-$47.15 M(+6.0%)
Sept 2018
-
-$12.46 M(+18.2%)
-$44.48 M(-1.2%)
June 2018
-
-$10.54 M(-9.1%)
-$45.03 M(-5.3%)
Mar 2018
-
-$11.59 M(+17.3%)
-$47.55 M(-7.7%)
Dec 2017
-$51.51 M(+19.4%)
-$9.88 M(-24.0%)
-$51.51 M(+0.4%)
Sept 2017
-
-$13.01 M(-0.4%)
-$51.30 M(+3.2%)
June 2017
-
-$13.06 M(-16.0%)
-$49.69 M(+4.1%)
Mar 2017
-
-$15.55 M(+60.6%)
-$47.73 M(+10.6%)
Dec 2016
-$43.16 M
-$9.68 M(-15.1%)
-$43.16 M(-2.0%)
DateAnnualQuarterlyTTM
Sept 2016
-
-$11.40 M(+2.8%)
-$44.02 M(+59.8%)
June 2016
-
-$11.09 M(+1.0%)
-$27.55 M(+8.7%)
Mar 2016
-
-$10.98 M(+4.1%)
-$25.35 M(+3.9%)
Dec 2015
-$24.40 M(-26.8%)
-$10.55 M(-308.0%)
-$24.40 M(-11.8%)
Sept 2015
-
$5.07 M(-157.0%)
-$27.67 M(-13.7%)
June 2015
-
-$8.90 M(-11.3%)
-$32.07 M(-5.0%)
Mar 2015
-
-$10.03 M(-27.4%)
-$33.75 M(+1.2%)
Dec 2014
-$33.35 M(+42.4%)
-$13.82 M(-2159.3%)
-$33.35 M(+1788.6%)
Sept 2014
-
$671.00 K(-106.3%)
-$1.77 M(-86.8%)
June 2014
-
-$10.57 M(+9.8%)
-$13.42 M(-33.9%)
Mar 2014
-
-$9.63 M(-154.2%)
-$20.30 M(-13.4%)
Dec 2013
-$23.43 M(-29.8%)
$17.77 M(-261.7%)
-$23.43 M(-54.7%)
Sept 2013
-
-$10.99 M(-37.0%)
-$51.72 M(+4.9%)
June 2013
-
-$17.45 M(+36.7%)
-$49.31 M(+26.2%)
Mar 2013
-
-$12.76 M(+21.3%)
-$39.06 M(+17.1%)
Dec 2012
-$33.36 M(+66.0%)
-$10.52 M(+22.6%)
-$33.36 M(+14.2%)
Sept 2012
-
-$8.58 M(+19.3%)
-$29.21 M(+10.7%)
June 2012
-
-$7.19 M(+1.8%)
-$26.39 M(+10.1%)
Mar 2012
-
-$7.07 M(+10.9%)
-$23.96 M(+19.2%)
Dec 2011
-$20.10 M(+40.1%)
-$6.37 M(+10.6%)
-$20.10 M(+16.5%)
Sept 2011
-
-$5.76 M(+21.0%)
-$17.25 M(+14.3%)
June 2011
-
-$4.76 M(+48.7%)
-$15.09 M(+8.8%)
Mar 2011
-
-$3.20 M(-9.1%)
-$13.87 M(-3.3%)
Dec 2010
-$14.34 M(-28.7%)
-$3.52 M(-2.2%)
-$14.34 M(-1.2%)
Sept 2010
-
-$3.60 M(+1.8%)
-$14.52 M(+33.0%)
June 2010
-
-$3.54 M(-3.9%)
-$10.91 M(+47.9%)
Mar 2010
-
-$3.68 M(-0.4%)
-$7.38 M(+99.6%)
Dec 2009
-$20.12 M(-2.6%)
-$3.70 M
-$3.70 M
Dec 2008
-$20.66 M
-
-

FAQ

  • What is AcelRx Pharmaceuticals annual net profit?
  • What is the all time high annual net income for AcelRx Pharmaceuticals?
  • What is AcelRx Pharmaceuticals quarterly net profit?
  • What is the all time high quarterly net income for AcelRx Pharmaceuticals?
  • What is AcelRx Pharmaceuticals TTM net profit?
  • What is the all time high TTM net income for AcelRx Pharmaceuticals?

What is AcelRx Pharmaceuticals annual net profit?

The current annual net income of ACRX is -$18.40 M

What is the all time high annual net income for AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals all-time high annual net profit is $47.76 M

What is AcelRx Pharmaceuticals quarterly net profit?

The current quarterly net income of ACRX is -$4.52 M

What is the all time high quarterly net income for AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals all-time high quarterly net profit is $70.66 M

What is AcelRx Pharmaceuticals TTM net profit?

The current TTM net income of ACRX is -$18.40 M

What is the all time high TTM net income for AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals all-time high TTM net profit is $48.28 M